Mumbai, November 30, 2017: Pharma Major, Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strengths of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg.
The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure (hypertension),company said in afiling with BSE.
Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
United News of India